HomepageD4S ⢠FRA
add
Daiichi Sankyo
Vorige slotkoers
ā¬Ā 21,42
Dag-range
ā¬Ā 21,16 - ā¬Ā 21,16
Jaar-range
ā¬Ā 18,02 - ā¬Ā 37,90
Beurswaarde
47,24Ā mld. USD
Gem. volume
160,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
TYO
Marktnieuws
INTC
5,53%
Financiƫle informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY) | jun 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 474,60Ā mld. | 8,81% |
Bedrijfskosten | 285,54Ā mld. | 15,07% |
Netto inkomsten | 85,50Ā mld. | 0,14% |
Netto winstmarge | 18,02 | -7,97% |
Winst per aandeel | ā | ā |
EBITDA | 114,51Ā mld. | 4,49% |
Effectief belastingtarief | 18,91% | ā |
Balans
Totale activa
Totale passiva
(JPY) | jun 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 574,30Ā mld. | -28,68% |
Totale activa | 3,46Ā bln. | 0,65% |
Totale passiva | 1,88Ā bln. | 9,60% |
Totaal aandelenvermogen | 1,58Ā bln. | ā |
Uitstaande aandelen | 1,85Ā mld. | ā |
Koers-boekwaardeverhouding | 0,03 | ā |
Rendement op activa | 6,99% | ā |
Rendement op kapitaal | 13,80% | ā |
Kasstroom
Nettomutatie in liquide middelen
(JPY) | jun 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 85,50Ā mld. | 0,14% |
Operationele kasstroom | -36,57Ā mld. | 66,77% |
Kasstroom uit beleggingen | -815,00Ā mln. | -100,23% |
Kasstroom uit financiering | -19,15Ā mld. | 82,19% |
Nettomutatie in liquide middelen | -65,54Ā mld. | -141,46% |
Vrije kasstroom | -15,84Ā mld. | -106,31% |
Over
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
Opgericht
1899
Hoofdvestiging
Website
Werknemers
19.765